Every 10-Q that Privia Health Group, Inc. (PRVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PRVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRVA filings page.
Privia Health Group, Inc. generated higher results for the quarter ended June 30, 2026. Revenue was $632.6 million, up from $521.2 million a year earlier, and net income attributable to Privia Health Group, Inc. was $9.0 million versus $2.7 million. Adjusted EBITDA rose to $37.4 million.
Growth was driven by both fee-for-service and value-based care, with Practice Collections at $970.0 million, 5,644 Implemented Providers and 1.647 million Attributed Lives. Cash and cash equivalents were $412.2 million, total assets $1.49 billion, and there were no borrowings on an expanded $250 million revolving credit facility.
The company continues to expand geographically, including a 77% acquisition of a New Jersey medical group, and reports significant goodwill and intangible assets tied to payer contracts and physician networks. It also notes payer concentration among three large payers and an information request from federal and state authorities related to a former affiliated practice, which it is addressing in cooperation with the agencies.
Privia Health Group, Inc. reported strong growth for the three months ended March 31, 2026, with revenue rising to $603.8 million from $480.1 million, driven mainly by higher fee-for-service patient care and value-based care revenue.
Care Margin increased to $128.7 million, Platform Contribution to $67.0 million, and Adjusted EBITDA to $36.7 million, showing improved operating leverage. Net income attributable to Privia Health declined to $3.1 million from $4.2 million as a higher effective tax rate and increased stock-based compensation offset operating gains.
Privia Health Group (PRVA) reported Q3 results highlighting strong growth and solid liquidity. Revenue reached $580.4 million, up from $437.9 million, with operating income of $14.4 million versus $5.8 million. Net income attributable to Privia was $6.9 million ($0.05 diluted EPS), compared with $3.5 million a year ago. Value-based care momentum continued as shared savings benefited from a $23.8 million change in estimate tied to the 2024 MSSP performance.
Cash and cash equivalents were $441.4 million, and no amounts were drawn on the $125 million revolving credit facility. Accounts receivable rose to $499.0 million, reflecting higher volumes and VBC accruals, while provider liability increased to $495.7 million. The company closed the PMG-AZ acquisition, adding $64.4 million of payer/physician network intangibles and $30.6 million of goodwill; PMG-AZ contributed $37.0 million of revenue post-close.
After quarter-end, Privia received $156.9 million from CMS for 2024 MSSP shared savings, of which $88.4 million will be disbursed to providers, and signed a definitive agreement to acquire an ACO business from Evolent Health for $100.0 million in cash plus up to $13.0 million, subject to customary conditions.
Privia Health Group (PRVA) posted solid top-line growth in Q2 2025. Revenue rose 23.4 % to $521.2 million, driven by stronger Value-Based Care (capitated +34 % to $75.5 million; shared-savings +51 % to $60.0 million) and fee-for-service patient care of $331.5 million. Six-month revenue reached $1.00 billion, up 19.5 % year-over-year. Gross profit improved 14.8 % to $112.8 million.
Earnings moderated. Operating income fell to $3.3 million (-34.6 %), and net income attributable to PRVA slipped to $2.7 million (EPS basic $0.02 vs. $0.03). YTD net income rose 7.1 % to $6.9 million on better first-quarter results.
Cash deployment and balance sheet. The company closed a 51 % acquisition of Privia Medical Group Arizona for $89.1 million cash, lifting goodwill to $172.2 million and intangibles to $170.1 million. Cash & equivalents declined to $390.1 million from $491.1 million at year-end, reflecting the deal and a $16.1 million operating cash outflow. No borrowings are outstanding on the $125 million revolver; total debt remains zero. Stockholders’ equity increased to $733.5 million on share issuance and retained earnings.
Key operating metrics. Implemented providers grew 13.8 % to 5,125, and attributed lives rose 15.2 % to 1.38 million. Practice collections reached $862.9 million (+18.5 %). Provider liability climbed to $458.1 million, and accounts receivable to $444.0 million.
Management continues to highlight expansion into 16 markets, including recent entries into Indiana and Arizona, and underscores the shift toward higher-margin VBC contracts while maintaining a strong liquidity position.